CATALYST PHARMACEUTICALS, INC. — Revenue by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/48ef4359-8fb0-4e4f-8963-0605797084c7/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $589.0M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-071525 |
| FY 2024 | $491.7M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-027714 |
| FY 2023 | $398.2M | 2023-01-01 – 2023-12-31 | evidence 0001193125-24-050908 |
| FY 2022 | $214.2M | 2022-01-01 – 2022-12-31 | evidence 0001193125-23-071299 |
| FY 2021 | $140.8M | 2021-01-01 – 2021-12-31 | evidence 0001193125-22-077228 |
| FY 2020 | $119.1M | 2020-01-01 – 2020-12-31 | evidence 0001193125-22-077228 |
| FY 2019 | $102.3M | 2019-01-01 – 2019-12-31 | evidence 0001193125-22-077228 |
| FY 2018 | $500.0k | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-078253 |
| FY 2017 | $0 | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-082292 |
| FY 2016 | $0 | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-083667 |
| FY 2015 | $0 | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-505167 |
| FY 2014 | $0 | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-091323 |
| FY 2013 | $0 | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-091323 |
| FY 2012 | $0 | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-091323 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CATALYST PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income